한글목차

임핀지(더발루맙) 시장 규모는 최근 급성장하고 있습니다. 2025년 301만 달러에서 2026년에는 336만 달러에 이르고, CAGR 11.4%의 성장이 전망되고 있습니다. 지난 수년간의 성장은 면역관문억제제의 임상적 성공, 폐암 발병률 증가, 종양학 분야의 규제 당국의 승인, 생존율 향상, 그리고 제약업계의 적극적인 투자에 기인한 것으로 보입니다.

임핀지(더발루맙) 시장 규모는 향후 몇 년간 급성장이 전망됩니다. 2030년에는 511만 달러에 이르고, CAGR은 11.1%를 나타낼 전망입니다. 예측 기간 동안의 성장 요인으로는 새로운 암 적응증 확대, 면역치료 접근성 향상, 종양학 임상시험 증가, 헬스케어 분야 의료비 증가(종양학 분야), 병용요법 프로토콜 개발 등을 꼽을 수 있습니다. 예측 기간 동안 주요 동향으로는 PD-L1 억제제의 도입 확대, 폐암에서의 면역치료 확대, 면역종양학 병용요법의 성장, 바이오마커 기반 치료에 대한 관심 증가, 여러 고형암에 대한 폭넓은 사용 등이 있습니다.

암 발생률 증가는 향후 몇 년 동안 임핀지(durvalumab) 시장의 성장을 가속할 것으로 예측됩니다. 암은 비정상적인 세포의 통제할 수 없는 증식과 확산을 특징으로 하는 질병군으로, 정상적인 신체 조직에 침입하여 손상을 입힐 수 있습니다. 암 발생률 증가는 주로 고령화에 기인합니다. 암 위험은 나이가 들면서 증가하며, 흡연, 부적절한 식습관, 비만 등의 생활습관 요인도 암 발생률 증가에 기여하고 있습니다. 임핀지(성분명: durvalumab)는 PD-L1 단백질을 억제하여 암세포가 면역체계의 감지를 피하는 것을 방지하는 암 치료제로 사용됩니다. 예를 들어, 미국 정부기관인 국립암연구소(NIH)에 따르면, 2022년 현재 미국에는 1,810만 명의 암 생존자가 있으며, 이 숫자는 2032년까지 2,250만 명으로 늘어날 것으로 예측됩니다. 따라서 암 발생률 증가가 임핀지(듀발루맙) 시장 확대를 주도하고 있습니다.

향후 개인맞춤형 헬스케어의 부상은 임핀지(듀발루맙) 시장의 성장을 견인할 것으로 예측됩니다. 개인 맞춤형 헬스케어는 유전자 프로파일, 환경, 생활습관 등 환자 개개인의 특성에 따라 치료 전략을 맞춤화하여 보다 정밀하고 효과적인 치료 결과를 얻을 수 있는 헬스케어 접근법입니다. 맞춤의료의 확대는 유전체 기술의 발전, 분자생물학에 대한 깊은 이해, 정밀 진단 도구의 가용성 향상, 그리고 부작용을 줄이면서 치료 효과를 높이는 표적치료에 대한 수요 증가에 의해 촉진되고 있습니다. 임핀지(성분명: durvalumab)는 PD-L1 단백질을 표적으로 억제함으로써 특정 종양 생물학 및 면역 특성에 기반한 개별화된 면역치료 접근을 가능하게 하고, 치료 효과를 높이고 불필요한 부작용을 최소화하여 맞춤형 의료를 지원합니다. 예를 들어, 미국에 본사를 둔 대표 단체인 맞춤형 의료연합(Personalized Medicine Coalition)에 따르면, 2022년 미국 식품의약국(FDA)이 승인한 신약의 34%가 맞춤형 의료 관련이며, 지난 8년간 신규 승인 건수의 최소 25%를 차지했다고 합니다. 를 차지합니다. 따라서 맞춤형 의료의 성장이 임핀지(듀발루맙) 시장 확대를 견인하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 한국 시장

제17장 서유럽 시장

제18장 영국 시장

제19장 독일 시장

제20장 프랑스 시장

제21장 동유럽 시장

제22장 북미 시장

제23장 미국 시장

제24장 캐나다 시장

제25장 남미 시장

제26장 중동 시장

제27장 아프리카 시장

제28장 시장 규제 상황과 투자환경

제29장 경쟁 구도와 기업 개요

제30장 세계 시장 경쟁 벤치마킹과 대시보드

제31장 주요 인수합병(M&A)

제32장 시장 잠재력이 높은 국가, 부문, 전략

제33장 부록

영문목차

Imfinzi (durvalumab) is a human monoclonal antibody and an immunotherapy medication developed to inhibit programmed death-ligand 1 (PD-L1), a protein that cancer cells use to evade the immune system. It is indicated for the treatment of several cancers, including non-small cell lung cancer, small cell lung cancer, biliary tract cancer, and advanced urothelial carcinoma.

The main types of Imfinzi (durvalumab) include 2.4 mL injections and 10 mL injections. A 2.4 mL injection refers to a defined volume of the medication supplied in a 2.4 milliliter vial or syringe, commonly used to ensure accurate dosing in clinical treatments or procedures. These formulations are distributed through hospital pharmacies, retail pharmacies, and online pharmacies and are used for various applications such as locally advanced urothelial carcinoma, metastatic urothelial carcinoma, and others.

Tariffs have impacted the Imfinzi market by increasing costs related to monoclonal antibody production inputs, sterile injection packaging, and temperature controlled logistics. These impacts are most evident in regions reliant on imported biologics such as asia pacific and eastern europe. Hospital oncology budgets face pricing pressures due to higher acquisition costs. At the same time, tariffs have encouraged regional biologics manufacturing investments. This improves long term supply stability and reduces dependence on global trade routes.

The imfinzi (durvalumab) market research report is one of a series of new reports from The Business Research Company that provides imfinzi (durvalumab) market statistics, including imfinzi (durvalumab) industry global market size, regional shares, competitors with a imfinzi (durvalumab) market share, detailed imfinzi (durvalumab) market segments, market trends and opportunities, and any further data you may need to thrive in the imfinzi (durvalumab) industry. This imfinzi (durvalumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The imfinzi (durvalumab) market size has grown rapidly in recent years. It will grow from $3.01 million in 2025 to $3.36 million in 2026 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to clinical success of immune checkpoint inhibitors, rising lung cancer prevalence, regulatory approvals in oncology, improved survival outcomes, strong pharmaceutical investment.

The imfinzi (durvalumab) market size is expected to see rapid growth in the next few years. It will grow to $5.11 million in 2030 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to expansion into new cancer indications, increased immunotherapy accessibility, growth in oncology clinical trials, rising healthcare oncology spending, development of combination protocols. Major trends in the forecast period include rising adoption of pd-l1 inhibitors, expansion of immunotherapy in lung cancer, growth of combination immuno oncology regimens, increased focus on biomarker driven therapies, broader use across multiple solid tumors.

The increasing incidence of cancer is expected to propel the growth of the Imfinzi (durvalumab) market in the coming years. Cancer is a group of diseases marked by the uncontrolled growth and spread of abnormal cells that can invade and damage normal body tissues. The rising incidence of cancer is largely attributed to an aging population, as cancer risk increases with age, along with lifestyle factors such as smoking, poor dietary habits, and obesity, which contribute to higher cancer rates. Imfinzi (durvalumab) is used in cancer treatment by blocking the PD-L1 protein, thereby preventing cancer cells from escaping immune system detection. For instance, in May 2024, according to the National Cancer Institute (NIH), a US-based government agency, there were 18.1 million cancer survivors in the United States in 2022, a number projected to increase to 22.5 million by 2032. Therefore, the growing incidence of cancer is driving the expansion of the Imfinzi (durvalumab) market.

The rise of personalized medicine is expected to drive the growth of the Imfinzi (durvalumab) market going forward. Personalized medicine is a healthcare approach that customizes treatment strategies based on individual patient characteristics, including genetic profile, environment, and lifestyle, to achieve more precise and effective outcomes. The expansion of personalized medicine is driven by advances in genomic technologies, deeper understanding of molecular biology, increased availability of precision diagnostic tools, and growing demand for targeted therapies that improve outcomes while reducing adverse effects. Imfinzi (durvalumab), through its targeted inhibition of the PD-L1 protein, supports personalized medicine by enabling tailored immunotherapy approaches based on specific tumor biology and immune characteristics, thereby improving treatment effectiveness and minimizing unnecessary side effects. For example, according to the Personalized Medicine Coalition, a US-based representative organization, personalized medicines accounted for 34% of new drug approvals by the FDA in 2022, and represented at least 25% of new approvals over the previous eight years. Therefore, the growth of personalized medicine is fueling the Imfinzi (durvalumab) market.

Major companies operating in the Imfinzi (durvalumab) market are focusing on expanding indications, such as perioperative use in combination with chemotherapy, to strengthen their competitive position. For instance, in January 2023, AstraZeneca plc, a UK-based biopharmaceutical company, announced that IMFINZI combined with chemotherapy more than doubled the pathological complete response rate in patients with resectable early-stage gastric and gastroesophageal junction cancers compared to chemotherapy alone. This approach involved a two-phase treatment strategy, including pre-surgical and post-surgical administration, and demonstrated sustained immune activation benefits. This expansion into gastrointestinal cancer indications highlights AstraZeneca's strategy to broaden its clinical applications and support long-term adoption, although it also introduces regulatory challenges due to the need for additional clinical evidence and health economic assessments for more complex treatment regimens.

Major companies operating in the imfinzi (durvalumab) market are AstraZeneca PLC.

North America was the largest region in the imfinzi (durvalumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the imfinzi (durvalumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the imfinzi (durvalumab) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

The imfinzi (durvalumab) market consists of sales of products including Keytruda, Opdivo, Tecentriq, Libtayo, Bavencio and Emerging PD-1/PD-L1 Inhibitors. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Imfinzi (durvalumab) Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses imfinzi (durvalumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for imfinzi (durvalumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The imfinzi (durvalumab) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: 2.4mL Injection; 10mL Injection
• 2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 3) By Application: Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Other Applications
• Companies Mentioned: AstraZeneca PLC.
• Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Imfinzi (durvalumab) Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Imfinzi (durvalumab) Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Imfinzi (durvalumab) Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Imfinzi (durvalumab) Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Rising Adoption Of Pd-L1 Inhibitors
  • 4.2.2 Expansion Of Immunotherapy In Lung Cancer
  • 4.2.3 Growth Of Combination Immuno Oncology Regimens
  • 4.2.4 Increased Focus On Biomarker Driven Therapies
  • 4.2.5 Broader Use Across Multiple Solid Tumors

5. Imfinzi (durvalumab) Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Oncology Clinics
• 5.3 Cancer Treatment Centers
• 5.4 Specialty Pharmacies
• 5.5 Research Institutions

6. Imfinzi (durvalumab) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Imfinzi (durvalumab) Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Imfinzi (durvalumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Imfinzi (durvalumab) Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Imfinzi (durvalumab) Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Imfinzi (durvalumab) Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Imfinzi (durvalumab) Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Imfinzi (durvalumab) Market Segmentation

• 9.1. Global Imfinzi (durvalumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 2.4mL Injection, 10mL Injection
• 9.2. Global Imfinzi (durvalumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
• 9.3. Global Imfinzi (durvalumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Other Applications

10. Imfinzi (durvalumab) Market Regional And Country Analysis

• 10.1. Global Imfinzi (durvalumab) Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Imfinzi (durvalumab) Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Imfinzi (durvalumab) Market

• 11.1. Asia-Pacific Imfinzi (durvalumab) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Imfinzi (durvalumab) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Imfinzi (durvalumab) Market

• 12.1. China Imfinzi (durvalumab) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Imfinzi (durvalumab) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Imfinzi (durvalumab) Market

• 13.1. India Imfinzi (durvalumab) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Imfinzi (durvalumab) Market

• 14.1. Japan Imfinzi (durvalumab) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Imfinzi (durvalumab) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Imfinzi (durvalumab) Market

• 15.1. Australia Imfinzi (durvalumab) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. South Korea Imfinzi (durvalumab) Market

• 16.1. South Korea Imfinzi (durvalumab) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 16.2. South Korea Imfinzi (durvalumab) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. Western Europe Imfinzi (durvalumab) Market

• 17.1. Western Europe Imfinzi (durvalumab) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. Western Europe Imfinzi (durvalumab) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. UK Imfinzi (durvalumab) Market

• 18.1. UK Imfinzi (durvalumab) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. Germany Imfinzi (durvalumab) Market

• 19.1. Germany Imfinzi (durvalumab) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. France Imfinzi (durvalumab) Market

• 20.1. France Imfinzi (durvalumab) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. Eastern Europe Imfinzi (durvalumab) Market

• 21.1. Eastern Europe Imfinzi (durvalumab) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 21.2. Eastern Europe Imfinzi (durvalumab) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. North America Imfinzi (durvalumab) Market

• 22.1. North America Imfinzi (durvalumab) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 22.2. North America Imfinzi (durvalumab) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. USA Imfinzi (durvalumab) Market

• 23.1. USA Imfinzi (durvalumab) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 23.2. USA Imfinzi (durvalumab) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Canada Imfinzi (durvalumab) Market

• 24.1. Canada Imfinzi (durvalumab) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 24.2. Canada Imfinzi (durvalumab) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. South America Imfinzi (durvalumab) Market

• 25.1. South America Imfinzi (durvalumab) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 25.2. South America Imfinzi (durvalumab) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Middle East Imfinzi (durvalumab) Market

• 26.1. Middle East Imfinzi (durvalumab) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Middle East Imfinzi (durvalumab) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Africa Imfinzi (durvalumab) Market

• 27.1. Africa Imfinzi (durvalumab) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 27.2. Africa Imfinzi (durvalumab) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. Imfinzi (durvalumab) Market Regulatory and Investment Landscape

29. Imfinzi (durvalumab) Market Competitive Landscape And Company Profiles

• 29.1. Imfinzi (durvalumab) Market Competitive Landscape And Market Share 2024
  • 29.1.1. Top 10 Companies (Ranked by revenue/share)
• 29.2. Imfinzi (durvalumab) Market - Company Scoring Matrix
  • 29.2.1. Market Revenues
  • 29.2.2. Product Innovation Score
  • 29.2.3. Brand Recognition
• 29.3. Imfinzi (durvalumab) Market Company Profiles
  • 29.3.1. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

30. Global Imfinzi (durvalumab) Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Imfinzi (durvalumab) Market

32. Imfinzi (durvalumab) Market High Potential Countries, Segments and Strategies

• 32.1 Imfinzi (durvalumab) Market In 2030 - Countries Offering Most New Opportunities
• 32.2 Imfinzi (durvalumab) Market In 2030 - Segments Offering Most New Opportunities
• 32.3 Imfinzi (durvalumab) Market In 2030 - Growth Strategies
  • 32.3.1 Market Trend Based Strategies
  • 32.3.2 Competitor Strategies

33. Appendix

• 33.1. Abbreviations
• 33.2. Currencies
• 33.3. Historic And Forecast Inflation Rates
• 33.4. Research Inquiries
• 33.5. The Business Research Company
• 33.6. Copyright And Disclaimer